I think it's way too early to tell if the data is worthless or not.
I remember a lot of people, back in 2015, saying the same about Anavex because it was a P1A trial with only 32 people and no placebo, no blinds, etc.
The difference between CRTX and AVXL is that CRTX has IPO money behind it. There are vested interests that want to see it succeed. The good news is that it demonstrates AVXL is significantly undervalued if one accepts CRTX's market cap of $1.8B as being fairly valued. But anyone who says that CRTX is BS, or anything of the sort isn't being objective either because it's way too early to know if that company has stumbled onto something groundbreaking.
I see a lot of parallels between AVXL in 2015 and CRTX today. I also feel bad for early CRTX investors because if those parallels hold true, they have a long and bumpy road ahead of them.
News 
Market Data 
Discover 
